Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics

References

• McKeever A, Alderman SE, Luff S, et al. Assessment and care of childbearing women with severe and persistent mental illness. Nurs Womens Health. 2016;20(6):486–499.
   Google Scholar
• Zumstein N, Riese F. Defining severe and persistent mental illness – a pragmatic utility concept analysis. Front Psychiatry. 2020 Jul 6;11: 648.
   PubMed Web of Science ®Google Scholar
• Butler H, O’Brien AJ. Access to specialist palliative care services by people with severe and persistent mental illness. A retrospective cohort study. Int J Ment Health Nu. 2018;27(2):737–746.
   PubMed Web of Science ®Google Scholar
• Donald EE, Stajduhar KI. A scoping review of palliative care for persons with severe persistent mental illness. Palliat Support Care. 2019;17(4):479–487. .
   PubMed Web of Science ®Google Scholar
• Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020 Aug 11;8:CD008016. .
   PubMedGoogle Scholar
• Pacchiarotti I, Tiihonen J, Kotzalidis GD, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychopharmacol. 2019 Apr;29(4):457–470.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
   PubMed Web of Science ®Google Scholar
• Kishi T, Ikuta T, Matsuda Y, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry 2020 Nov 11. https://doi.org/10.1038/s41380-020-00946-6
   Google Scholar
• Lindström L, Lindström E, Nilsson M, et al. Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis. J Affect Disord. 2017;213:138–150.
   PubMed Web of Science ®Google Scholar
• Jones J, Chandra PS, Dazzan P, et al. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet. 2014;384(9956):1789–1799.
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010;16(5):306–324.
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Slade EP, Medoff DR, et al. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res. 2011;131(1–3):127–132.
   PubMed Web of Science ®Google Scholar
• Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105(3):164–172.
   PubMed Web of Science ®Google Scholar
• Boyce P, Irwin L, Morris G, et al. Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder. A critical review of the evidence. Bipolar Disord. 2018;20(Suppl. 2):25–36. .
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213.
   PubMed Web of Science ®Google Scholar
• Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-analyses of randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(9):38.
   Web of Science ®Google Scholar
• Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13(1):340.
   PubMed Web of Science ®Google Scholar
• Keramatian K, Chakrabarty T, Yatham LM. Long-acting injectable second-generation/atypical antipsychotics for the management of bipolar disorder: a systematic review. CNS Drugs. 2019;33(5):431–456.
   PubMed Web of Science ®Google Scholar
• Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220–230.
   PubMed Web of Science ®Google Scholar
• Ghossoub E, Minchin S, Hayreh D, et al. Long-acting injectable versus oral antipsychotics for restoration of competency to stand trial. J Am Acad Psychiatry Law. 2019;47(4):440–447.
   PubMed Web of Science ®Google Scholar
• Verdoux H, Pambrun E, Tournier M, et al. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study. Acta Psychiatr Scand. 2017;135(5):429–438.
   PubMed Web of Science ®Google Scholar
• Mei-Dan E, Ray JG, Vigod SN. Perinatal outcomes among women with bipolar disorder: a population-based cohort study. Am J Obstet Gynecol. 2015;212(3):367.e1–8.
   PubMed Web of Science ®Google Scholar
• McAllister-Williams RH, Baldwin DS, Cantwell R, et al. endorsed by the british association for psychopharmacology. (2017). British Association for Psychopharmacology (BAP). Consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum. J Psychopharmacol. 2017;31(5):519–552.
   PubMed Web of Science ®Google Scholar
• Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ. 2016;532:h5918.
   PubMed Web of Science ®Google Scholar
• Faruk, Orsolini Faruk U, Orsolini L, Eds. Perinatal psychopharmacology. 1st edition ed. Switzerland: Springer; 2019.
   Google Scholar
• Petersen I, McCrea LR, Osborn DJ, et al. Discontinuation of antipsychotic medication in pregnancy: a cohort study schizophrenia research. 2014;159:1218–1225.
   Google Scholar
• Petersen I, McCrea RL, Sammon CJ, et al. Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. Health Technol Assess. 2016;20(23):1–176. .
   PubMed Web of Science ®Google Scholar
• Ellfolk M, Leinonen MK, Gissler M, et al. Second-generation antipsychotics and pregnancy complications. Eur J Clin Pharmacol. 2020;76(1):107–115.
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Hernandez-Diaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–946. .
   PubMed Web of Science ®Google Scholar
• Breadon C, Kulkarni J. An update on medication management of women with schizophrenia in pregnancy. Expert Opin Pharmacother. 2019;20(11):1365–1376.
   PubMed Web of Science ®Google Scholar
• Vigod SN, Gomes T, Wilton AS, et al. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350(may11 5):h2298.
   PubMed Web of Science ®Google Scholar
• Tosato S, Albert U, Tomassi S, et al. A systematized review of atypical antipsychotics in pregnant women: balancing between risks of untreated illness and risks of drug-related adverse effects. J Clin Psychiatry. 2018;78(5):e477–e489. .
   Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.
   PubMed Web of Science ®Google Scholar
• Gentile S, Tofani S, Bellantuono C. Aripiprazole and pregnancy: a case report and literature review. J Clin Psychopharmacol. 2011;31(4):531–532.
   PubMed Web of Science ®Google Scholar
• Bellantuono C, Di Massimo G, Mauro A, et al. [Aripiprazole in pregnancy: a review of literature]. Riv Psichiatr. 2015;50(1):8–11.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry. 2017;78(3):324–331. .
   PubMed Web of Science ®Google Scholar
• Cuomo A, Goracci A, Fagiolini A. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. J Affect Disord. 2018;228:229–237.
   PubMed Web of Science ®Google Scholar
• Damkier P, Videbech P. The safety of second-generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs. 2018;32(4):351–366.
   PubMed Web of Science ®Google Scholar
• Cuomo A, Beccarini Crescenzi B, Goracci A, et al. Drug safety evaluation of aripiprazole in bipolar disorder. Expert Opin Drug Saf. 2019;18(6):455–463.
   PubMed Web of Science ®Google Scholar
• FDA (Food and Drug Administration). Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Federal Register. (2014). [cited 2020 Oct 10]. Availablefrom: https://www.federalregister.gov/documents/2014/12/04/2014-28241/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for.
   Google Scholar
• Gentile S. A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. Expert Opin Drug Saf. 2014;13(12):1733–1742.
   PubMed Web of Science ®Google Scholar
• Windhager E, Kim SW, Saria A, et al. Perinatal use of aripiprazole: plasma levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol. 2014;34(5):637–641.
   PubMed Web of Science ®Google Scholar
• Westin AA, Brekke M, Molden E, et al. Treatment with antipsychotics in pregnancy: changes in drug disposition. Clin Pharmacol Ther. 2018;103(3):477–484.
   PubMed Web of Science ®Google Scholar
• Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2015;116(4):315–320.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, León-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: focus on bipolar disorder. Eur Neuropsychopharmacol. 2016;26(10):1562–1578.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329.
   PubMed Web of Science ®Google Scholar
• Sabo T, Bosnjak D, Oreskovic V, et al. Influence of pharmacokinetic features of long acting injectable ARI in pregnancy. Eur Psychiatry. 2018;48S:S359–S566.
   Google Scholar
• Ballester-Gracia I, Pérez-Almarcha M, Galvez-Llompart A, et al. Use of long acting injectable ARI before and through pregnancy in bipolar disorder: a case report. BMC Pharmacol Toxicol. 2019;20(1):52.
   PubMed Web of Science ®Google Scholar
• Fernandez-Abscal B, Rocio-Barbero M, Saenz-Herrero M, et al. Long-acting injectable aripripazole in pregnant women with schizophrenia: a case-series report. Ther Adv Psychopharmacol. 2021;11:1–2.
   Web of Science ®Google Scholar
• Mendhekar DN, Sunder KR, Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord. 2006a;8(3):299–300.
   PubMed Web of Science ®Google Scholar
• Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother. 2006b;40(3):575.
   PubMed Web of Science ®Google Scholar
• Mervak B, Collins J, Valenstein M. Case-report of aripiprazole usage during pregnancy. Arch Womens Ment Health. 2008;11:249–250.
   PubMed Web of Science ®Google Scholar
• Lutz UC, Hiemke C, Wiatr G, et al. Aripiprazole in pregnancy and lactation: a case report. J Clin Psychopharmacol. 2010;30(2):204–205.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Teoh S, Hackett LP, et al. Placental transfer of aripiprazole. Aust N Z J Psychiatry. 2011;45(6):500–501.
   PubMed Web of Science ®Google Scholar
• Widschwendter CG, Hofer A. Aripiprazole use in early pregnancy: a case report. Pharmacopsychiatry. 2012;45(7):299–300.
   PubMed Web of Science ®Google Scholar
• Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health. 2009;12(1):53–57.
   PubMed Web of Science ®Google Scholar
• Paulus W. Is the use of aripiprazole safe during first trimester of pregnancy? Reprod Toxicol. 2013;37(87):2013.
   Google Scholar
• Habermann F, Fritzsche J, Fuhlbru¨ck F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–462.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Worsley R, Gilbert H, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One. 2014;9(5):e94788. .
   PubMed Web of Science ®Google Scholar
• Bellet F, Beyens MN, Bernard N, et al. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiol Drug Saf. 2015;24(4):368–380.
   PubMed Web of Science ®Google Scholar
• Cohen LS, Viguera AC, McInerney KA, et al. Reproductive safety of second-generation antipsychotics: current data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. Am J Psychiatry. 2016;173(3):263–270.
   PubMed Web of Science ®Google Scholar
• Sakai T, Ohtsu F, Mori C, et al. Signal of miscarriage with aripiprazole: a disproportionality analysis of the japanese adverse drug event report database. Drug Saf. 2017;40(11):1141–1146.
   PubMed Web of Science ®Google Scholar
• Galbally M, Frayne J, Watson SJ, et al. Aripiprazole and pregnancy: a retrospective, multicentre study. J Affect Disord. 2018;238:593–596.
   PubMed Web of Science ®Google Scholar
• Park Y, Hernandez-Diaz S, Bateman BT, et al. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry. 2018;175(6):564–574. .
   PubMed Web of Science ®Google Scholar
• Schlotterbeck P, Leube D, Kircher T, et al. Aripiprazole in human milk. Int J Neuropsychopharmacol. 2007;10:433.
   PubMed Web of Science ®Google Scholar
• Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. J Clin Psychopharmacol. 2016;36(3):244–252.
   PubMed Web of Science ®Google Scholar
• Frew JR. Psychopharmacology of bipolar I disorder during lactation: a case report of the use of lithium and aripiprazole in a nursing mother. Arch Womens Ment Health. 2015;18(1):135–136.
   PubMed Web of Science ®Google Scholar
• Uguz F, Orsolini L (Eds). (2019). Perinatal psychopharmacology. 1st edition. Switzerland: Spinger. https://doi.org/10.1007/978-3-319-92919-4.
   Google Scholar
• Manouilenko I, Ohman I, Georgieva J. Long-acting OLA injection during pregnancy and breastfeeding: a case report. Arch Womens Ment Health. 2018;21(5):587–589.
   PubMed Web of Science ®Google Scholar
• McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4):444–449.
   PubMed Web of Science ®Google Scholar
• Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6(10):1221–1286.
   PubMedGoogle Scholar
• Peng M, Gao K, Ding Y, et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berl). 2013;228(4):577–584.
   PubMed Web of Science ®Google Scholar
• Sadowski A, Todorow M, Yazdani Brojeni P, et al. Pregnancy outcomes following maternal exposure to secondgeneration antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7):e003062.
   PubMed Web of Science ®Google Scholar
• Teodorescu A, Ifteni P, Moga MA, et al. Dilemma of treating schizophrenia during pregnancy: a case series and a review of literature. BMC Psychiatry. 2017;17(1):311.
   PubMed Web of Science ®Google Scholar
• Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36(3):518–533.
   PubMed Web of Science ®Google Scholar
• Brunner E, Falk DM, Jones M, et al. OLA in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013;14(1):38.
   PubMed Web of Science ®Google Scholar
• Arora M, Praharaj SK. Meningocele and ankyloblepharon following in utero exposure to olanzapine. Eur Psychiatry. 2006;21(5):345–346.
   PubMed Web of Science ®Google Scholar
• Spyropoulou AC, Zervas IM, Soldatos CR. Hip dysplasia following a case of olanzapine exposed pregnancy: a questionable association. Arch Womens Ment Health. 2006;9(4):219–222.
   PubMed Web of Science ®Google Scholar
• Yeshayahu Y. The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. Am J Psychiatry. 2007;164(11):1759–1760.
   PubMed Web of Science ®Google Scholar
• Ramkisson R, Campbell M, Agius M. The clinical dilemma–prescribing in pregnancy. Psychiatr Danub. 2008;20(1):88–90.
   PubMed Web of Science ®Google Scholar
• Sørensen MJ, Kjaersgaard MIS, Pedersen HS, et al. Risk of fetal death after treatment with antipsychotic medications during pregnancy. PLoS One. 2015;10(7):e0132280. .
   PubMed Web of Science ®Google Scholar
• Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, et al. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009;70(2):247–258.
   PubMed Web of Science ®Google Scholar
• Bodén R, Lundgren M, Brandt L, et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715–721.
   PubMed Web of Science ®Google Scholar
• Babu GN, Desai G, Tippeswamy H, et al. Birth weight and use of olanzapine in pregnancy: a prospective comparative study. J Clin Psychopharmacol. 2010;30(3):331–332.
   PubMed Web of Science ®Google Scholar
• Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008 May;192(5):333–337.
   PubMed Web of Science ®Google Scholar
• Vemuri M, Rasgon N. A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain. J Clin Psychiatry. 2007;68(12):12. 1989.
   Web of Science ®Google Scholar
• Frise C, Attwood B, Watkinson P, et al. Life-threatening ketoacidosis in a pregnant woman with psychotic disorder. Obstet Med. 2016;9(1):46–49.
   PubMed Web of Science ®Google Scholar
• Convertino I, Sansone A, Marino A, et al. Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects. Drug Saf. 2016;39:903–924.
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Kristensen JH, Begg EJ, et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry. 2003;160(8):1428–1431. .
   PubMed Web of Science ®Google Scholar
• Klinger G, Stahl B, Fusar-Poli P, et al. Antipsychotic drugs and breastfeeding. Pediatr Endocrinol Rev. 2013;10(3):308–317.
   PubMed Web of Science ®Google Scholar
• Gilad O, Merlob P, Stahl B, et al. Outcome of infants exposed to olanzapine during breastfeeding. Breastfeed Med. 2011;6(2):55–58.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kumar RC, Smith B, et al. Psychotropic drugs in breast milk: no evidence for adverse effects on prepulse modulation of startle reflex or on cognitive level in infants. Dev Psychobiol. 1998;32(3):249–256.
   PubMed Web of Science ®Google Scholar
• Onken M, Mick I, Schaefer C. Paliperidone and pregnancy-an evaluation of the German embryotox database. Arch Womens Ment Health. 2018;21(6):657–662.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol. 2018;11(6):625–639.
   PubMed Web of Science ®Google Scholar
• Binns R, O’Halloran SJ, Teoh S, et al. Placental transfer of paliperidone during treatment with a depot formulation. J Clin Psychopharmacol. 2017;37(4):474–475.
   PubMed Web of Science ®Google Scholar
• Özdemir AK, Pak ŞC, Canan F, et al. Paliperidone palmitate use in pregnancy in a woman with schizophrenia. Arch Womens Ment Health. 2015;18(5):739–740.
   PubMed Web of Science ®Google Scholar
• Zamora Rodríguez FJ, Benítez Vega C, Sánchez-Waisen Hernández MR, et al. Use of paliperidone palmitate throughout a schizoaffective disorder patient’s gestation period. Pharmacopsychiatry. 2017;50(1):38–40.
   PubMed Web of Science ®Google Scholar
• Hill RC, McIvor RJ, Wojnar-Horton RE, et al. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breastfeeding. J Clin Psychopharmacol. 2000;20(2):285–286.
   PubMed Web of Science ®Google Scholar
• Ilett KF, Hackett LP, Kristensen JH, et al. Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacother. 2004;38(2):273–276.
   PubMed Web of Science ®Google Scholar
• Aichhorn W, Stuppaeck C, Whitworth AB. Risperidone and breast-feeding. J Psychopharmacol. 2005;19(2):211–213.
   PubMed Web of Science ®Google Scholar
• Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. J Clin Psychiatry. 2002;63(1):76–77.
   PubMed Web of Science ®Google Scholar
• Skopek M, Manoj P. Hyperprolactinaemia during treatment with paliperidone. Australas Psychiatry. 2010;18(3):261–263.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Hemels ME, Nuamah I, et al. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Ann Pharmacother. 2012;46(10):1322–1330.
   PubMed Web of Science ®Google Scholar
• Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):315–320. .
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim KM, Kim JM, et al. Use of long-acting injectable RIS before and throughout pregnancy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):543–545.
   PubMed Web of Science ®Google Scholar
• Clinebell K, Gannon J, Debrunner S, et al. Long-acting RIS injections in a pregnant patient with bipolar disorder. Bipolar Disord. 2017;19(7):606‐607.
   PubMed Web of Science ®Google Scholar
• Coppola D, Russo LJ, Kwarta RF Jr., et al. Evaluating the postmarketing experience of RIS use during pregnancy: pregnancy and neonatal outcomes. Drug Saf. 2007;30(3):247–264.
   PubMed Web of Science ®Google Scholar
• Dabbert D, Heinze M. Follow-up of a pregnancy with risperidone microspheres. Pharmacopsychiatry. 2006;39(6):235.
   PubMed Web of Science ®Google Scholar
• Mendhekar D, Lohia D. Risperidone therapy in two successive pregnancies. J Neuropsychiatry Clin Neurosci. 2008;20(4):485–486.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Salgado B. Risperidone safety in pregnancy. A case report. 2008;36(6):366–368. Actas Esp Psiquiatr.
   PubMed Web of Science ®Google Scholar
• Levinson AJ, McKenna AKE, Koren G, et al. Pregnancy outcome in women receiving atypical antipsychotic drugs: a prospective, multicentre, controlled study. Schizophr Res. 2003;60(suppl 1):361. .
   Web of Science ®Google Scholar
• Grover S, Avasthi A. Risperidone in pregnancy: a case of oligohydramnios. 2004;7:56–57. German J Psychiatry.
   Google Scholar
• Koren G. The effect of ascertainment bias in evaluating gestational antidepressant exposure. J Popul Ther Clin Pharmacol. 2011;18:e174–5.
   PubMedGoogle Scholar
• Galbally M, Frayne J, Watson SJ, et al. Psychopharmacological prescribing practices in pregnancy for women with severe mental illness: a multicentre study. Eur Neuropsychoparmacol. 2019;29(1):57–64. .
   PubMed Web of Science ®Google Scholar
• Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177–184.
   PubMed Web of Science ®Google Scholar
• Epstein RA, Bobo WV, Shelton RC, et al. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. Pharmacoepidemiol Drug Saf. 2013;22(7):794–801.
   PubMed Web of Science ®Google Scholar
• Leong C, Raymond C, Château D, et al. Psychotropic drug use before, during, and after pregnancy: a population-based study in a Canadian cohort (2001–2013). Can J Psychiatry. 2017;62(8):543–550. .
   PubMed Web of Science ®Google Scholar
• Park Y, Huybrechts KF, Cohen JM, et al. Antipsychotic medication use among publicly insured pregnant women in the United States. Psychiatr Serv. 2017;68(11):112–119. .
   PubMed Web of Science ®Google Scholar
• Tandon R. Bridging the efficacy-effectiveness gap in the antipsychotic treatment of schizophrenia: back to the basics. J Clin Psychiatry. 2014;75(11):e1321–e1322.
   PubMed Web of Science ®Google Scholar
• Anderson KN, Ailes EC, Lind JN, et al. National Birth Defects Prevention Study. Atypical antipsychotic use during pregnancy and birth defect risk: national Birth Defects Prevention Study, 1997–2011. Schizophr Res. 2020Jan;215:81–88.
   PubMed Web of Science ®Google Scholar
• Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry. 2013;202(5):321–323.
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4): 1001–1020. .
   PubMedGoogle Scholar
• Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J. Psychiatr Pract. 2009;15(3):183–192.
   PubMed Web of Science ®Google Scholar
• Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28(3):279–288.
   PubMed Web of Science ®Google Scholar
• Raffi ER, Nonacs R, Cohen LS. Safety of Psychotropic Medications During Pregnancy. Clin Perinatol. 2019;46(2):215–234.
   PubMed Web of Science ®Google Scholar
• Coughlin CG, Blackwell KA, Bartley C, et al. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125(5):1224–1235.
   PubMed Web of Science ®Google Scholar
• Cohen LS, Góez-Mogollón L, Sosinsky AZ, et al. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry. 2018;175(12):1225–1231.
   PubMed Web of Science ®Google Scholar
• Uguz F. Antipsychotic Use During Pregnancy and the Risk of Gestational Diabetes Mellitus: a Systematic Review. J Clin Psychopharmacol. 2019;39(2):162–167.
   PubMed Web of Science ®Google Scholar
• Parikh T, Goyal D, Scarff JR, et al. Antipsychotic drugs and safety concerns for breast-feeding infants. South Med J. 2014;107(11):686–688.
   PubMed Web of Science ®Google Scholar
• Taylor CL, Broadbent M, Khondoker M, et al. Predictors of severe relapse in pregnant women with psychotic or bipolar disorders. J Psychiatr Res. 2018;104:100–107.
   PubMed Web of Science ®Google Scholar
• Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007 Dec;164(12):1817–1824. .
   PubMed Web of Science ®Google Scholar
• Wesseloo R, Kamperman AM, Munk-Olsen T, et al. Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: a Systematic Review and Meta-Analysis. Am J Psychiatry. 2016 Feb 1;173(2):117–127. .
   PubMed Web of Science ®Google Scholar
• Bergink V, Bouvy PF, Vervoot JS, et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry. 2012 Jun;169(6):609–615. .
   PubMed Web of Science ®Google Scholar
• Schaffer AL, Zoega H, Tran DT, et al. Trajectories of antipsychotic use before and during pregnancy and associated maternal and birth characteristics. Aust N Z J Psychiatry. 2019;53(12):1208–1221.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Epub 2011 Mar 1. Erratum in: Am. J. Psychiatry. 169(2), 223. Am J Psychiatry. 2011;1686:603–609.
   PubMed Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561.
   PubMed Web of Science ®Google Scholar
• Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829.
   PubMed Web of Science ®Google Scholar
• Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198–219.
   PubMedGoogle Scholar
• Morell R, Curtis J, Watkins A, et al. Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication. Psychiatry Res. 2019;281:112606.
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(Suppl 16):18–23.
   PubMed Web of Science ®Google Scholar
• Westin AA, Brekke M, Molden E, et al. Treatment with antipsychotics in pregnancy: changes in drug disposition. Clin Pharmacol Ther. 2018 Mar;103(3):477–484. .
   PubMed Web of Science ®Google Scholar
• Reinstein SA, Cosgrove J, Malekshahi T, et al. Long-acting injectable antipsychotic use during pregnancy: a brief review and concise guide for clinicians. J Clin Psychiatry. 2020 Nov 24;81(6):20ac13597.
   PubMed Web of Science ®Google Scholar
• NICE. Psychosis and schizophrenia in adults: prevention and management. London: NICE; 2014. [cited 2020 Oct 10]. Available from:  https://www.nice.org.uk/guidance/cg178
   Google Scholar
• The American Psychiatric Association (APA). Practice guideline for the treatment of patients with schizophrenia. Third Editioned.; 2021. Washington DC: American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890424841
   Google Scholar